Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Is  (ZTS) Outperforming Other Medical Stocks This Year?

Has Zoetis (ZTS) Outpaced Other Medical Stocks This Year?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session

Zoetis, Inc. (ZTS) CEO Juan Ramon Alaix on Q2 2019 Results - Earnings Call Transcript

Spending is taking a bite out of the bottom line, and livestock products continue to perform poorly, but that didn't keep the animal health leader from increasing its outlook for the year.

Zoetis Keeps Growing, but Headwinds Persist

Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

Zoetis (NYSE: ZTS) reported second-quarter earnings of 90 cents per share, which beat the analyst consensus estimate of 82 cents by 9.76%.

Zoetis Reports Q2 Earnings Beat, Raises Guidance

Zoetis earnings came in better than expected for the second quarter, with the animal health specialist raising guidance. Zoetis stock is trading near highs.

Zoetis Earnings Top Views, Guidance Raised

Proshares Pet Care ETF

PetIQ

In 2019, U.S. pet owners are expected to spend more than $75 billion dollars on their animals.

3 Charts That Suggest It's Time to Buy Pet Stocks

Zoetis Inc. (NYSE: ZTS) will acquire Platinum Performance, a nutrition-focused animal health company for an undisclosed amount.

Zoetis Will Acquire Platinum Performance

American Water Works

American Express

Corning

Home Depot

Lockheed Martin

Southwest Airlines

Starbucks

Sherwin-Williams

Visa

It’s no secret that investors love their dividends. Investors praise companies that can raise their dividends year after year, and a commitment to a strong dividend policy is a company’s representation that it has faith in its earnings power well into the future.

10 Dividends That Can See Double-Digit Growth for 5 Years or Longer

Catalent

CTLT vs. ZTS: Which Stock Is the Better Value Option?

Copart

Intuit

MarketAxess Holdings

WellCare Health Plans

We have highlighted five top-ranked stocks that have led the S&P 500's five-year run from 2,000 to 3,000.

5 Top-Ranked Stocks That Powered S&P 500 Rally

Zoetis (ZTS) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Zoetis (ZTS) Now

Zoetis Inc’s (NYSE: ZTS) stock has appreciated significantly year-to-date on a continued “safety haven” trade and upside to 2020 results on the basis of the upcoming launch of Simparica Trio, according to Bank of America Merrill Lynch.

BofA Downgrades Veterinary Medicine Maker Zoetis On Valuation

Zoetis has been one of our holdings since 2014 and has more than doubled in value, reaching another all-time high last week.

Zoetis: High-Quality Compounder Growing 10% Per Year

ZTS stock is higher by roughly 30% year-to-date, but it is also extremely overbought. Traders can eye Zoetis for a mean-reversion move lower.

Trade of the Day: Zoetis Stock Screams Overbought

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Zoetis (ZTS) Down 0.8% Since Last Earnings Report: Can It Rebound?

ABIOMED

Aptiv Holdings Ltd

Grupo Aeroportuario del Sureste SAB de CV

Sarepta Therapeutics

Chief investment officer and chief executive officer of Sands Capital Management, Frank Sands (Trades, Portfolio), bought shares of the following stocks in the fourth quarter of 2018 and first quarter of 2019.

7 Stocks Frank Sands Continues to Buy

Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

Zoetis, Inc. (ZTS) CEO Juan Ramon Alaix on Q1 2019 Results - Earnings Call Transcript

Zoetis (ZTS) delivered earnings and revenue surprises of 11.39% and -0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Tops Q1 Earnings Estimates

Teva Pharmaceutical

Generic drug giant Teva Pharmaceutical and animal drug specialist Zoetis both beat earnings views early Thursday. Teva stock rose.

Teva, Zoetis Earnings Top Views

The animal health leader is quietly running laps around the S&P 500.

3 Things You Might Not Know About Zoetis

Vertex Pharmaceuticals

To take some of the complexity of investing in pharma stocks, look at the companies that dominate their markets.

News for Zoetis Stock (ZTS)